Abstract. Plant cytokinins and auxins have recently been proposed as novel cancer therapies, which proceed via different mechanisms; however, their combined use has not been investigated. To the best of our knowledge, the present study was the first to show that the cytokinin ortho-methoxytopolin-riboside (MeoTR) strongly inhibited the proliferation of HeLa cells, the effect of which was synergistically enhanced by auxin indole-3-acetic acid (IAA), while IAA demonstrated to have no cytotoxic effects on cells. MeoTR was found to activate intrinsic and extrinsic caspase-dependent pathways, and IAA potentiated this activation. In addition, these effects were blocked by Z-Val-Ala-Asp-fluoromethylketone (Z-VAD-FM K), a pan-specific-caspase-inhibitor. IAA increased the MeoTRinduced inhibition of B cell lymphoma 2 (Bcl-2) and survivin, whereas IAA-only decreased Bcl-2 expression. MeoTR downregulated phosphorylated (p)-pyruvate dehydrogenase kinase 1, p-Akt and p-glycogen synthase kinase 3β, the effect of which was more potent in combination with IAA, despite the weak effect of IAA alone. LY294002, an Akt-inhibitor, was able to increase the inhibition of p-Akt through MeoTR and combination treatment. IAA and MeoTR increased the proportion of cells in S phase independently. However, the combination treatment induced a further increase. In addition, IAA and MeoTR treatment downregulated protein levels of cyclin A, cyclin-dependent kinase 2 (CDK2) and p-CDK2, and upregulated protein levels of p21 and p27. Furthermore, the combination treatment enhanced these effects, indicating that IAA potentiated the inhibitory effect of MeoTR on HeLa cells via cell cycle progression arrest and accumulation in S phase, coupled with the negative regulation of Bcl-2. In conclusion, the results of the present study suggested that treatment with these two phytohormones in combination, may offer a novel therapeutic strategy for the treatment of malignant cervical cancer.
Introduction
Cytokinins are critical hormones for plant growth and development. Historically, they were defined by their ability to promote cell division when combined with auxin in tobacco tissue culture (1) . Further studies demonstrated that cytokinins were involved in several processes in plants (2) . Chemically, cytokinins are N 6 -substituted adenine derivatives (3) . Cytokinins are divided into three categories, according to their substituent, as follows: Isoprenoid cytokinins, including isopentenyladenine, zeatin and zeatin riboside; furfural derivatives, including kinetin and kinetin riboside; and aromatic cytokinins, including ortho-topolin riboside (oTR), ortho-methoxytopolin-riboside (MeoTR) and N 6 -benzyladenosine (4) . Since the first aromatic cytokinin oTR was isolated from mature leaves of poplar (5) , aromatic cytokinins have also been detected in oil palm (6) and microalgae (7) . Previous studies have shown that aromatic cytokinins exhibit toxicity against different types of human cancer cells and their effectiveness in the treatment of tumors was reported to be mediated through inhibition of cell proliferation and/or differentiation (8) (9) (10) (11) . N 6 -benzyladenosine was found to induce cell cycle arrest and apoptosis in bladder carcinoma T24 cells (12) . A previous study revealed that oTR had a strong apoptosis-inducing effect on the human hepatoma SMMC-7721 cell line (11) . MeoTR and oTR share an identical parental structure, except for the substitution of the hydroxyl in benzene with a methoxy group. However, the effect of MeoTR on human cancer cells has not yet been studied.
Indole-3-acetic acid (IAA) is a naturally present auxin and a vital regulator of plant cell division, elongation and differentiation (13) . Previous studies have shown that IAA affected several different mammalian cell functions; IAA, activated by horseradish peroxidase (HRP) (14, 15) or intense pulsed light (16, 17) , was found to exhibit potent toxicity against cancer cells, including G361 human melanoma cells (14) and PC-3 prostate cancer cells (18) . However, the effect of IAA treatment alone against tested cancer cells did not produce significant results (14, 17, 18) . Furthermore, to the best of our knowledge, a comparative and systematic study of the effects of a combination treatment with cytokinin and auxin on human cancer cells has yet to be performed.
The aim of the present study was to investigate the inhibitory effects of MeoTR and/or IAA in the human cervical cancer HeLa cell line. We showed that treatment with MeoTR alone arrested cell cycle progression, and accumulated in S phase, and induced apoptosis via intrinsic and extrinsic caspase-dependent pathways in vitro. These effects were enhanced by combination treatment with IAA. Although IAA did not affect cell proliferation, it induced significant cell accumulation in S phase, indicating that its potentiating effect on MeoTR may be mediated by its cytostatic rather than cytotoxic activity. MeoTR treatment blocked the Akt pathway, and these effects were enhanced by IAA, although IAA had no effect on the Akt pathway when used alone.
Materials and methods
Reagents. MeoTR was purchased from OlChemIm Ltd. (Olomouc, Czech Republic) and IAA, Z-Val-Ala-Asp-fluo romethylketone (Z-VAD-FMK), LY294002 and violet staining solution were purchased from Sigma-Aldrich (St. Louis, MO, USA). Insulin-like growth factor I (IGF-I), an Akt activation factor, was purchased from PeproTech, Inc. (Rocky Hill, CT, USA). The maximum final concentration of dimethyl sulfoxide (DMSO) in the culture medium was <0.5%. XTT and phenazine methosulfate (PMS) were purchased from Sangon Biotech Co., Ltd (Shanghai, China). All additional solid reagents were purchased from Sigma-Aldrich. The following primary antibodies: Monoclonal anti-cleaved poly-adenosine diphosphate-ribose polymerase (PARP; cat. no. 5625), polyclonal anti-total PARP (cat. no. 9542), monoclonal anti-cytochrome c (cat. no. 11940), monoclonal anti-B cell lymphoma 2 (Bcl-2; cat. no. 2870), monoclonal anti-survivin (cat. no. 2808), monoclonal anti-phosphorylated (p)-pyruvate dehydrogenase kinase 1 (PDK1; cat. no. 3438), monoclonal anti-p-Akt (Ser473; cat. no. 4060), monoclonal anti-Akt (cat. no. 4685), monclonal anti-p-glycogen synthase kinase 3β (GSK-3β; cat. no. 5558), monoclonal anti-GSK-3β (cat. no. 12456) and monoclonal anti-β-actin (cat. no. 3700), were purchased from Cell Signaling Technology, Inc. (Beverly, MA, USA). The following primary antibodies: Polyclonal anti-cyclin A (cat. no. sc-751), polyclonal anti-p-cyclin-dependent kinase 2 (CDK2) (Thr160) (cat. no. sc-101656), polyclonal anti-CDK2 (cat. no. sc-163), polyclonal anti-p21 (cat. no sc-397) and polyclonal anti-p27 (cat. no. sc-528), were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA) and primary antibodies, polyclonal anti-caspase-3 (cat. no. 29010), polyclonal anti-caspase-9 (cat. no. 22978) and polyclonal anti-caspase-8 (cat. no. 22977) were purchased from Signalway Antibody (College Park, MD, USA). Goat anti-mouse (#7072) and goat anti-rabbit (#7071) secondary IgG antibodies were purchased from Cell Signaling Technology, Inc.
Cell culture. Human cervical cancer HeLa cells (Cell Bank of the Chinese Academy of Sciences, Shanghai, China) were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum, 100 µg/ml penicillin and 100 µg/ml streptomycin in a humidified atmosphere containing 5% CO 2 at 37˚C.
Cell viability assay. Vehicle (0.4% DMSO)-treated cells were considered the control cells. Cell viability was determined using the XTT assay. HeLa cells were seeded in 96-well plates at a density of 5.0x10 4 cells/well for 12 h prior to treatment. For the dose-dependent assay, solutions containing various concentrations of MeoTR (25, 50, 75 and 100 µM) and IAA (20, 50 , 100, 500 and 1000 µM), independently, or MeoTR (25, 50, 75 and 100 µM) in combination with 1 mM IAA were added to each well in 100 µl RPMI-1640 medium and incubated for 48 h. For the time course assay, solutions containing 50 µM MeoTR and 1 mM IAA, alone or in combination, were added to each well in 100 µl RPMI-1640 medium and incubated for 0, 12, 24 and 48 h. Following treatment, 50 µl XTT solution (1 g/l XTT and 5 mg/l PMS in RPMI-1640 medium) was added to each well for a further 4 h at 37˚C. Absorbance was read at 595 nm using a microplate reader (Thermo Electron Corporation, Waltham, MA, USA). Three independent experiments were performed from six replicates of each treatment group. The percentage cell viability was calculated as follows: [sample optical density (OD)/control OD] x100%.
The coefficient of drug interaction (CDI) was used to analyze the synergistically inhibitory effect of drug combinations. CDI=AB/(AxB), where AB represents the cell viability of the combination group and A or B represent the cell viabilities of the single agent groups, as determined by measuring the absorbance of each group. CDI<1 indicates that the drugs are synergistic; CDI=1 indicates that the drugs are additive; CDI>1 indicates that the drugs are antagonistic; in addition, CDI <0.7 indicates that the drugs are significantly synergistic, as previously described (19) .
Crystal violet staining. HeLa cells were seeded in 6-well plates at a density of 5.0x10 4 cells/well for 12 h. The cells were treated with MeoTR (50 and 100 µM) and/or 1 mM IAA for a further 48 h. Cells were then fixed with 4% paraformaldehyde and stained with crystal violet staining solution. The cell morphology was observed using a Nikon Eclipse Ti-U Multi-port inverted microscope (Nikon Corp., Tokyo, Japan).
Flow cytometric analysis of apoptosis and cell cycle. Cell apoptosis and cell cycle distribution were analyzed using flow cytometry. HeLa cells were pre-treated with MeoTR (50 and 100 µM) and/or 1 mM IAA for 48 h. Cell apoptosis was assessed using a fluorescein isothiocyanate-Annexin V apoptosis kit (BD Biosciences, San Jose, CA, USA) according to the manufacturer's instructions. The stained cells were then analyzed using a FACSCalibur flow cytometer (BD Biosciences). For cell cycle analysis, HeLa cells were harvested and washed twice with ice-cold phosphate-buffered saline (PBS), resuspended in 1 ml 75% ethanol (-20˚C) and fixed at -20˚C overnight. Fixed cells were washed with PBS, treated with 50 µg/ml RNase A for 5 min at room temperature and stained with propidium iodide (PI; 50 µg/ml) in the dark at 4˚C for 30 min. The stained cells were then assessed using a FACSCalibur flow cytometer. Each assay was performed in triplicate.
Western blotting. Following treatment with the indicated concentrations of MeoTR and/or 1 mM IAA for 48 h, the cells were lysed in RIPA lysis buffer. The concentration of total protein was determined using a bicinchoninic acid protein assay kit (Thermo Fisher Scientific, Waltham, MA, USA). For western blot analysis, 30 µg protein was resolved using 10% SDS-PAGE and transferred to polyvinylidene difluoride membranes. Blots were blocked in tris-buffered saline with Tween-20 (TBST), containing 0.01% Tween-20 and 5% non-fat dry milk for 1 h, and incubated with primary antibodies indicated above overnight at 4˚C with agitation. Membranes were then washed five times with TBST for 10 min each, followed by incubation with the indicated secondary antibodies for 2 h at 4˚C. Membranes were washed with TBST five times (10 min each) and peroxidase activity was visualized using the enhanced chemiluminescence method. Results were quantified through grey correlation analysis of bands using Image J software (National Institute of Health, Bethesda, MD, USA). Assays were performed in triplicate.
Statistical analysis.
Values are expressed as the mean ± standard error of the mean for three individual experiments. Statistical significance was determined using the Student's t-test. P<0.05 and P<0.01 were considered to indicate statistically significant differences between values. Fig. 1A . The effect of MeoTR and/or IAA on the survival of HeLa cells was assessed using an XTT assay. MeoTR alone or in combination with IAA was found to significantly decrease HeLa cell viability in dose-and time-dependent manners compared with that of the vehicle-treated control or MeoTR-treated cells, respectively (P<0.05) or P<0.01) (Fig. 1B , C and D), whereas IAA alone had no cytotoxic effects ( Fig. 1E and F) . MeoTR reduced HeLa cell viability to 54.1, 38.5, 27.1 and 21.0% of the control values at concentrations of 25, 50, 75 and 100 µM, respectively, and combination treatment with IAA further reduced cell viability to 47.5, 32.9, 18.3 and 11.3% at these concentrations, respectively ( Fig. 1B and D) . The CDI indicated that IAA acted significantly synergistically with MeoTR (Table I ). In addition, the potent growth inhibition of MeoTR alone and in combination (Fig. 1G) . Additionally, the obvious decrease of cell numbers, microscopic examination of cell morphology revealed certain major patterns of shape change in response to treatment with MeoTR alone or in combination with IAA. The treated cells were smaller, rounder and deep-stained compared with those of the control group, as well as detached from the culture well surface, indicating marked cell damage (Fig. 1G) .
Results

IAA enhances the effect of MeoTR on the inhibition of HeLa cell viability. The chemical structure of MeoTR is shown in
IAA enhances the effect of MeoTR on the induction of
HeLa cell apoptosis. In order to elucidate the mechanism of MeoTR-induced cell death, the pro-apoptotic effects of MeoTR were measured using flow cytometric analysis following Annexin V/PI staining. As shown in Fig. 2 , MeoTR induced cell apoptosis in a dose-dependent manner and combined treatment with IAA further enhanced this induction of apoptosis, while IAA alone was unable to induce apoptosis.
These findings indicated that apoptosis may contribute to the anti-proliferative effect of MeoTR in HeLa cells, the effect of which was enhanced in the presence of IAA.
MeoTR induces apoptosis through intrinsic and extrinsic caspase-dependent pathway and IAA potentiates this effect.
In order to investigate whether caspase-dependent apoptotic pathways were activated in response to MeoTR, HeLa cells were treated with different concentrations of MeoTR and/or 1 mM IAA for 48 h and then lysed for western blot analysis. The release of cytochrome c from mitochondria into the cytosol has an important role in the pro-apoptotic mechanisms of the intrinsic caspase-dependent pathways (20) . As shown in Fig. 3A , MeoTR treatment increased the cytosolic levels of cytochrome c in a dose-dependent manner, which led to the lysis of its downstream protein zymogen caspase-9. However, no changes in cytochrome c or caspase-9 were detected following pre-treatment with IAA alone (Fig. 4A) , Table I . Synergistically inhibitory effect of MeoTR and IAA combination treatment. whereas combination treatment with MeoTR and IAA was more demonstrated a more potent effect compared with that of MeoTR alone (Fig. 4A) . Caspase-8 is the key initiator caspase in the extrinsic caspase-dependent pathway and is activated by auto-phosphorylation (21, 22) . Treatment with MeoTR alone (Fig. 3B ) or in combination with IAA (Fig. 4B ) decreased the expression of the caspase-8 zymogen in a dose-dependent manner; in addition, the combination treatment was shown to accelerate the auto-phosphorylation of caspase-8, whereas treatment with IAA alone had no effect (Fig. 4B) . 
MeoTR induces the activation of caspase-3, induces the cleavage of PARP and downregulates anti-apoptotic
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proteins, and IAA potentiates this effect. PARP is the substrate of caspase-3, the executor of apoptosis and a marker of apoptosis. As shown in Fig. 3C , decreased pro-caspase-3 and increased cleaved PARP levels were observed in HeLa cells exposed to different concentrations of MeoTR (25, 50, 75 and 100 µM) in a dose-dependent manner, and this effect was enhanced when cells were treated with MeoTR in combination with 1 mM IAA (Fig. 4C) , whereas IAA alone did not affect the cleavage of pro-caspase-3 and PARP (Fig. 4C) .
In order to further confirm whether caspase cascade activation is involved in the apoptotic mechanism of MeoTR in combination with IAA, HeLa cells were pre-treated with 50 µM Z-VAD-FMK, a pan-specific-caspase-inhibitor (23) for 1 h, and exposed to 50 µM MeoTR and/or 1 mM IAA in the presence or absence of Z-VAD-FMK for a further 48 h. The MeoTR and/or IAA-mediated activation of caspase-3, decrease in total PARP and increase in cleaved PARP were found to be partially, but not completely, antagonized in the presence of Z-VAD-FMK; in addition, Z-VAD-FMK had no effect on IAA-only treatment (Fig. 4E) . These results indicated that MeoTR induced apoptosis in HeLa, which was enhanced by IAA, the mechanism of which may be associated with caspase activation.
Treatment of HeLa cells with increasing concentrations of MeoTR significantly decreased the levels of the anti-apoptotic proteins Bcl-2 and survivin (Fig. 3D) , the effect of which was potentiated by combination treatment with IAA (Fig. 4D) . Treatment of HeLa cells with 1 mM IAA alone downregulated Bcl-2, whereas survivin expression remained unchanged (Fig. 4D) .
MeoTR blocks the Akt signaling pathway and IAA potentiates this effect. In order to identify the signaling pathways involved in MeoTR-mediated apoptosis in HeLa cells, the Akt signaling pathway was investigated in HeLa cells following exposure to MeoTR in the presence or absence of IAA. As shown in Fig. 5A and B, Akt phosphorylation was inhibited in HeLa cells treated with MeoTR in a dose-dependent manner, the inhibitory effect of which was enhanced by combination treatment with IAA, whereas IAA alone had no effect on Akt phosphorylation. GSK-3β is a tumor suppressor gene regulated by the Akt signaling pathway, which is inactivated through phosphorylation (24) (25) (26) . MeoTR was found to strongly inhibit the phosphorylation of GSK-3β in a dose-dependent manner, the effect of which was enhanced by IAA ( Fig. 5A and B) , therefore protecting its tumor suppressor function.
In order to further confirm whether Akt inhibition was involved in this mechanism of MeoTR-mediated apoptosis, HeLa cells were pre-treated with 20 µM LY294002, an Akt inhibitor (27) for 30 min and exposed to 50 µM MeoTR and/or 1 mM IAA in the presence or absence of LY294002 for a further 48 h. As shown in Fig. 5C , pre-treatment with LY294002 significantly augmented the inhibitory effects of MeoTR on Akt phosphorylation, alone and in combination with IAA. In addition, following treatment with 50 µM MeoTR and/or 1 mM IAA in serum-free RPMI-1640 medium for 48 h, HeLa cells were stimulated by 10 nM IGF-I, an Akt activation factor (28) for 30 min. MeoTR alone, as well as combination with IAA, significantly inhibited the IGF-I-stimulated Akt activation (Fig. 5D) , therefore further confirming the inhibitory effect of MeoTR on the Akt 
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pathway, the effect of which was enhanced by combination treatment with IAA.
IAA enhances the inhibitory effect of MeoTR on HeLa cells through arresting cell cycle progression and accumulating in S-phase.
In order to investigate the potential synergistic inhibitory mechanism of MeoTR and IAA on HeLa cells, HeLa cells were treated with MeoTR (50 and 100 µM) and/or 1 mM IAA for 48 h and examined using flow cytometric analysis. MeoTR and IAA induced a marked accumulation of cells in S-phase, as indicated by the increased proportion of cells in S-phase, which was further enhanced by combination treatment with IAA. In addition, the effect of MeoTR alone or in combination with IAA cell cycle progression occurred in a dose-dependent manner ( Fig. 6A and B) .
The complex of cyclin A and CDK2 has a key role in the progression of cells from S-phase into G2/M-phase, and threonine phosphorylation of CDKs has been reported to enhance the binding of cyclins (29, 30) . As shown in Fig. 6C , treatment of HeLa cells with IAA or MeoTR, independently, attenuated the expression of cyclin A as well as that of total and p-CDK2; in addition, the combination treatment resulted in a more potent inhibitory effect. IAA and/or MeoTR treatment also resulted in a significant increase in p21 and p27 expression levels (Fig. 6C) , which were previously reported to inhibit the formation of CDK-cyclin complexes in order to negatively regulate the cell division cycle (31) . Overall, these results indicated that IAA synergistically enhanced MeoTR-induced anti-proliferative and apoptotic effects.
Discussion
MeoTR is a member of the aromatic cytokinin family. The results of the present study showed that MeoTR had a marked cytotoxic effect on HeLa cells (Fig. 1B) , while combination treatment with IAA enhanced the effect of MeoTR (Fig. 1D) . The effect of the combination treatment was further clarified through the calculation of CDI (Table I) .
Apoptosis is a physiological process that is critical for animal development and tissue homeostasis and is characterized by distinct morphological as well as biochemical features (32, 33) . In addition, two caspase-dependent pathways have been well characterized (34) , which are important for cell death induced by apoptosis (35) . The intrinsic caspase-dependent pathway is mediated by the release of cytochrome c from mitochondria into the cytosol (20) , where it promotes the interaction of apoptosis protein-activating factor 1 (APAF-1) and pro-caspase-9, leading to the formation of the apoptosome, which in turn results in the activation of the initiator caspase-9 (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) . In the extrinsic caspase-dependent pathway, caspase-8 is the key initiator caspase (21, 22) . The activation of the extrinsic pathway is Cells were pre-treated with MeoTR (50 and 100 µM) and/or IAA (1 mM) for 48 h, and or lysed for western blot analysis using specific antibodies. β-actin was used as an internal protein loading control. MeoTR, ortho-methoxytopolin-riboside; IAA, indole-3-acetic acid; CDK2, cyclin dependent kinase 2; p-, phosphorylated; PI, propidium iodide.
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A divided into two steps as follows: First, cell surface death receptors engage with their specific ligands, including CD95, tumor necrosis factor (TNF) receptor or TNF-related apoptosis-inducing ligand receptor, which results in the assembly of the death-inducing signal complex (DISC), allowing caspase-8 to reach a sufficient local concentration of zymogen and enzymatic activity; and secondly, the authophosphorylation and activation of caspase-8 triggers its separation from DISC, which enables it to access other substrates (37, 38) . Once the initiator caspases are activated by either the intrinsic or extrinsic signaling pathway, they trigger the activation of the effector caspases-3/7 and the cleavage of PARP, leading to the rapid and irreversible morphological and biochemical changes of apoptosis (39) .
In the present study, MeoTR treatment was found to increase the content of cytochrome c in the cytosol of HeLa cells, indicating the release of cytochrome c from mitochondria into the cytosol, and caspase-9 was activated (Fig. 3A) . In addition, the activation of the initiator caspase-8 was detected (Fig. 3B) . These results suggested that MeoTR-induced apoptosis in HeLa cells was mediated by the intrinsic and extrinsic caspase-dependent pathways. In cells exposed to combination treatment, the initiator proteins of the two pathways, caspase-9 and caspase-8, were activated and the degree of activation was increased ( Fig. 4A and B) ; however, IAA alone had no effect on the activation of these proteins or apoptosis (Fig. 4A,B, 2D ). These data further illustrate that the enhancement effect of IAA on MeoTR was not a simple superposition of cytotoxicity.
The intrinsic and extrinsic pathways are subject to negative regulation by numerous anti-apoptotic proteins, including Bcl-2 (40) and survivin (41, 42) . In the present study, when used independently, MeoTR downregulated these anti-apoptotic proteins, whereas IAA had no observable effect, with the exception of Bcl-2, which was negatively regulated by IAA ( Fig. 3D and 4D ). Combination treatment with MeoTR and IAA exhibited a more potent effect on reducing the expression of these anti-apoptotic proteins compared with that of each agent alone (Fig. 4D) . Therefore, downregulation of the expression of Bcl-2 may be one of the mechanisms underlying the potentiating effect of IAA on MeoTR-induced apoptosis.
The Akt pathway has a fundamental role in cell survival and proliferation, and is a potentially effective target for the development of novel drugs for the treatment of malignant cancers (43) (44) (45) . GSK-3β, a pro-apoptotic protein (24, 25) , acts downstream of the Akt pathway and upstream of caspase-8, and it is inactivated through phosphorylation at serine 9 mediated by the Akt pathway (26) . As shown in Fig. 5A in the present study, MeoTR alone attenuated the phosphorylation of Akt in a dose-dependent manner in HeLa cells. In addition, MeoTR and IAA combination treatment exhibited a more potent inhibitory effect on the phosphorylation of Akt compared with that of MeoTR alone (Fig. 5B ), although IAA alone had no effect (Fig. 5B) . The inhibition of Akt phosphorylation by MeoTR alone and in combination with IAA was further confirmed through the employment of specific Akt signal inhibitor LY294002 (Fig. 5C ) and the Akt activation factor IGF-I (Fig. 5D) . MeoTR inhibited the phosphorylation of GSK-3β (Fig. 5A) , thereby protecting its pro-apoptotic effect, and IAA potentiated the inhibitory effect of MeoTR on GSK-3β phosphorylation or the promotion of dephosphorylation (Fig. 5B) . In addition, the MeoTR-mediated inhibition of PDK1, an upstream regulator of the Akt pathway (43) , was comparably weak when used independently (Fig. 5A ) or in combination with IAA (Fig. 5B) , indicating that MeoTR may directly interfere with Akt phosphorylation and block this cell survival-promoting pathway. In summary, the regulation of the Akt pathway and GSK-3β activity by MeoTR and/or IAA may by the mechanism by which MeoTR mediated the suppression of survival and proliferation as well as the induction of apoptosis, and therefore contributed to the enhanced cytotoxicity of combination treatment.
Previous studies have shown that IAA activation by horseradish peroxidase or UVB may be used to investigate its effects on cancer cells, while IAA alone has a weak cytotoxic effect on the cell lines assessed (14) (15) (16) (17) 46, 47) . The results of the present study were in agreement with those of previous studies and showed that IAA had no effect on HeLa cell viability and apoptosis induction. However, the results of the present study demonstrated that IAA as well as MeoTR induced significant accumulation of cells in S-phase, inhibited the expression of S-phase-associated cyclin A, CDK2 and p-CDK as well as increased the expression of cell cycle-inhibitory proteins p21 and p27, with enhanced effects under combination treatment. These results suggested that IAA alone may induce significant delay in progression through S-phase (Fig. 6A-C) , which may therefore be the mechanism of IAA enhancement on MeoTR-induced growth arrest and apoptosis induction. In plant tissue culture, cytokinin and auxin are often used in combination to control cell division and differentiation; however, their combined effect on animal/human cancer cells in culture has not yet been reported. The results of the present study confirmed that MeoTR and IAA combination treatment exhibited a more potent effect on HeLa cell viability and apoptosis compared with that of MeoTR treatment alone.
In conclusion, the present results indicated that MeoTR exerted a marked anti-tumor effect on human cervical cancer HeLa cells through the induction of apoptosis and blockage of the Akt pathway, the effect of which was enhanced when treated in combination with IAA, while IAA alone had no cytotoxic effects. IAA therefore exhibited a synergistic effect on MeoTR-induced growth inhibition and apoptosis in HeLa cells through cell cycle progression arrest and accumulation in S-phase, coupled with the negative regulation of the Bcl-2. To the best of our knowledge, the present study was the first to demonstrated that cytokinin and auxin combination treatment had a synergistic antitumor effect in vitro, suggesting the potential effectiveness of combining two plant hormone-like substances for the future treatment of malignant cervical cancer. However, further studies, including pre-clinical studies and clinical trials, are required in order to support this proposed therapeutic strategy.
